%0 Journal Article
%T Bone Metastases in Metastatic Renal Cell Carcinoma: Now We Know That Cabozantinib Targets Bone Microenvironment | Insight Medical Publishing
%A Daniele Santini
%A Elena Verzoni
%A Giuseppe Procopio
%A Raffaele Ratta
%J ISSN: 2472-5056 NLM ID: 101685482
%D 2018
%R 10.21767/2472-5056.100054
%X The multiple tyrosine kinases inhibitor cabozantinib has shown improvements in progression-free survival (PFS), overall survival (OS) and objective response rate (ORR) in comparison to everolimus in patients with metastatic renal cell carcinoma (mRCC) in the METEOR trial, a phase III, randomized, open-label trial [1,2], leading to its approval in mRCC patients previously treated with antiangiogenic agents.
%U http://clinical-experimental-nephrology.imedpub.com/bone-metastases-in-metastatic-renal-cell-carcinoma-now-we-know-that-cabozantinib-targets-bone-microenvironment.php?aid=22182